108 related articles for article (PubMed ID: 38170789)
1. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates.
Prabhakaran M; Matassoli F; Leggat D; Hoover A; Srikanth A; Wu W; Henry AR; Wang J; Lin BC; Teng IT; Schramm CA; Castro M; Serebryannyy L; Jean-Baptiste N; Moore C; Gajjala S; Todd JM; McCarthy E; Narpala S; Francica J; Program VP; Corbett-Helaire KS; Douek DC; Kwong PD; Seder RA; Andrews SF; McDermott AB
Sci Transl Med; 2024 Jan; 16(728):eadd5960. PubMed ID: 38170789
[TBL] [Abstract][Full Text] [Related]
2. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Francica JR; Flynn BJ; Foulds KE; Noe AT; Werner AP; Moore IN; Gagne M; Johnston TS; Tucker C; Davis RL; Flach B; O'Connell S; Andrew SF; Lamb E; Flebbe DR; Nurmukhambetova ST; Donaldson MM; Todd JM; Zhu AL; Atyeo C; Fischinger S; Gorman MJ; Shin S; Edara VV; Floyd K; Lai L; Boyoglu-Barnum S; Van De Wetering R; Tylor A; McCarthy E; Lecouturier V; Ruiz S; Berry C; Tibbitts T; Andersen H; Cook A; Dodson A; Pessaint L; Van Ry A; Koutsoukos M; Gutzeit C; Teng IT; Zhou T; Li D; Haynes BF; Kwong PD; McDermott A; Lewis MG; Fu TM; Chicz R; van der Most R; Corbett KS; Suthar MS; Alter G; Roederer M; Sullivan NJ; Douek DC; Graham BS; Casimiro D; Seder RA
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315825
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
[TBL] [Abstract][Full Text] [Related]
4. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.
Joyce MG; King HAD; Elakhal-Naouar I; Ahmed A; Peachman KK; Macedo Cincotta C; Subra C; Chen RE; Thomas PV; Chen WH; Sankhala RS; Hajduczki A; Martinez EJ; Peterson CE; Chang WC; Choe M; Smith C; Lee PJ; Headley JA; Taddese MG; Elyard HA; Cook A; Anderson A; McGuckin Wuertz K; Dong M; Swafford I; Case JB; Currier JR; Lal KG; Molnar S; Nair MS; Dussupt V; Daye SP; Zeng X; Barkei EK; Staples HM; Alfson K; Carrion R; Krebs SJ; Paquin-Proulx D; Karasavva N; Polonis VR; Jagodzinski LL; Amare MF; Vasan S; Scott PT; Huang Y; Ho DD; de Val N; Diamond MS; Lewis MG; Rao M; Matyas GR; Gromowski GD; Peel SA; Michael NL; Bolton DL; Modjarrad K
Sci Transl Med; 2022 Feb; 14(632):eabi5735. PubMed ID: 34914540
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
6. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
8. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Amarilla AA; Modhiran N; Liang B; Li Z; Wijesundara DK; Lackenby JA; Griffin P; Bennet JK; Hensen L; Zhang W; Nguyen THO; Tran MH; Tapley P; Barnes J; Reading PC; Kedzierska K; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
EBioMedicine; 2023 Nov; 97():104842. PubMed ID: 37865043
[TBL] [Abstract][Full Text] [Related]
10. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
11. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses.
Mandolesi M; Sheward DJ; Hanke L; Ma J; Pushparaj P; Perez Vidakovics L; Kim C; Àdori M; Lenart K; Loré K; Castro Dopico X; Coquet JM; McInerney GM; Karlsson Hedestam GB; Murrell B
Cell Rep Med; 2021 Apr; 2(4):100252. PubMed ID: 33842900
[TBL] [Abstract][Full Text] [Related]
13. Deficient Generation of Spike-Specific Long-Lived Plasma Cells in the Bone Marrow After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Tehrani ZR; Habibzadeh P; Flinko R; Chen H; Abbasi A; Yared JA; Ciupe SM; Lewis GK; Sajadi MM
J Infect Dis; 2024 Feb; ():. PubMed ID: 38365441
[TBL] [Abstract][Full Text] [Related]
14. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
16. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
18. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
Front Immunol; 2021; 12():772240. PubMed ID: 34858430
[TBL] [Abstract][Full Text] [Related]
20. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
